Pharmaceutical company Jaguar Health has been granted until Feb. 13, 2023, to comply with Nasdaq's $1 bid price requirement, the company said Aug. 19.
Jaguar Health must report a closing bid price of $1 per share for 10 consecutive business days or face delisting from the stock index, according to an Aug. 19 company news release.
"We are pleased to have obtained additional time from Nasdaq to evidence compliance with the bid price requirement," Jaguar President and CEO Lisa Conte said. "Jaguar is focused on two late-stage clinical events in the next approximately six to 12 months that we expect to be transformational in terms of value creation and recognition for the company as we seek to regain compliance with the rule."